Elisabeth Sciotto, NP
Nurse Practitioner · Colorado Springs, CONPI 1699027565
Payments from drug & device makers
Across 127 payments — averaging $25.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$694
- Pfizer$403
- Neurocrine Biosciences, Inc.$356
- AstraZeneca$326
- Jazz Pharmaceuticals Inc.$215
- Bayer$158
- plus $1K from 27 others
What the payments were for
- Food & beverage$3,16099%
- Education$471%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 30 | $694 |
| Pfizer | 28 | $403 |
| Neurocrine Biosciences, Inc. | 12 | $356 |
| AstraZeneca(2 entities) | 10 | $326 |
| Jazz Pharmaceuticals Inc. | 3 | $215 |
| Bayer | 9 | $158 |
| Amgen(2 entities) | 5 | $123 |
| Argenx US, Inc. | 1 | $122 |
| Axsome Therapeutics, Inc. | 1 | $107 |
| Livanova USA, Inc. | 1 | $65 |
| Lundbeck LLC | 3 | $59 |
| TG Therapeutics, Inc. | 2 | $52 |
| Otsuka America Pharmaceutical, Inc. | 2 | $40 |
| Vanda Pharmaceuticals Inc. | 1 | $36 |
| Eisai Inc. | 1 | $34 |
| UCB, Inc. | 1 | $34 |
| SK Life Science, Inc. | 1 | $27 |
| Genentech USA, Inc. | 1 | $27 |
| Alkermes, Inc. | 1 | $26 |
| Boehringer Ingelheim | 1 | $25 |
| Sobi, Inc | 1 | $25 |
| GSK | 1 | $25 |
| GE HealthCare | 1 | $25 |
| Mallinckrodt Hospital Products Inc. | 1 | $23 |
| ANI Pharmaceuticals, Inc. | 1 | $22 |
| Springworks Therapeutics, Inc. | 1 | $22 |
| Seqirus USA Inc | 1 | $22 |
| Novo Nordisk | 1 | $21 |
| Exact Sciences | 1 | $21 |
| Supernus Pharmaceuticals, Inc. | 1 | $19 |
| Lilly USA, LLC | 1 | $19 |
| Acadia Pharmaceuticals Inc | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INGREZZA$251
- XYWAV$143
- ULTOMIRIS$126
- VYVGART HYTRULO$122
- Symbravo$107
How this compares
$3,207 in reported general payments places this provider in the 90th percentile of 1,384 nurse practitioner providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 25 | $30,777 |
| OzempicSemaglutide | 16 | $26,717 |
| RybelsusSemaglutide | 20 | $19,692 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 18 | $18,007 |
| TrulicityDulaglutide | 16 | $16,821 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $16,029 |
| FarxigaDapagliflozin Propanediol | 18 | $15,878 |
| MounjaroTirzepatide | 12 | $14,601 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 17 | $14,404 |
| EliquisApixaban | 17 | $11,386 |
| MyrbetriqMirabegron | 12 | $5,717 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $3,208 |
| Rosuvastatin Calcium | 130 | $1,950 |
| Levothyroxine Sodium | 189 | $1,863 |
| Omeprazole | 80 | $1,514 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $21 | $46,40936 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $25 | $45,18142 claims |
| AstraZenecaBreztri Aerosphere, Farxiga | $326 | $33,88536 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $19 | $31,42228 claims |
| GSKTrelegy Ellipta | $25 | $16,02916 claims |
| PfizerEliquis | $403 | $11,38617 claims |
| AbbVieSynthroid | $694 | $85515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,384 nurse practitioner providers in Colorado.
Other nurse practitioner in Colorado Springs
- Deborah HinnenColorado Springs$388K
- Lisa KeithColorado Springs$52K
- Brianne WagnerColorado Springs$11K
- Morgan TevlinColorado Springs$9K
- Jill SmothersColorado Springs$8K
- Tracey PutzColorado Springs$8K
- Chris SchabingerColorado Springs$7K
- Bridget CoyneColorado Springs$6K
- Anne ZobecColorado Springs$5K
- Kathryn BlairColorado Springs$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.